Nasdaq Acad News Today

Oppenheimer reiterated their market perform rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a report published on Monday morning, Benzinga reports. They currently have a $19.00 target price on the biopharmaceutical company’s stock. ACAD has been the topic of a number of other research reports. JPMorgan Chase & Co. decreased their price […]

Oppenheimer restated their market perform rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a research report released on Monday, Benzinga reports. The brokerage currently has a $19.00 target price on the biopharmaceutical company’s stock. A number of other brokerages have also recently commented on ACAD. Mizuho cut shares of ACADIA Pharmaceuticals from […]

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) CEO Stephen Davis sold 11,427 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $16.94, for a total transaction of $193,573.38. Following the transaction, the chief executive officer now owns 155,231 shares of the company’s […]

Cantor Fitzgerald restated their overweight rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a report released on Tuesday morning, Benzinga reports. Cantor Fitzgerald currently has a $37.00 price objective on the biopharmaceutical company’s stock. A number of other equities research analysts have also recently commented on ACAD. Royal Bank of Canada decreased […]

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) have earned an average rating of “Moderate Buy” from the fifteen research firms that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 1 […]

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report)‘s stock had its “overweight” rating reaffirmed by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $37.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 117.01% from […]

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report)‘s stock had its “overweight” rating reaffirmed by research analysts at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They presently have a $37.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 118.16% from the company’s current price. […]

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report)‘s stock had its “overweight” rating reissued by equities research analysts at Cantor Fitzgerald in a research report issued on Tuesday, Benzinga reports. They presently have a $37.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 118.16% from the stock’s […]

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) shares hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $16.60 and last traded at $16.74, with a volume of 1475997 shares traded. The stock had previously closed at $16.99. Wall Street Analyst Weigh In ACAD has been the […]

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report)’s stock price reached a new 52-week low during trading on Tuesday . The stock traded as low as $16.60 and last traded at $16.74, with a volume of 1475997 shares. The stock had previously closed at $16.99. Analyst Ratings Changes A number of analysts recently issued reports […]